Generic Name and Formulations:
Potassium (as bicarbonate and citrate) 10mEq, 20mEq, 25mEq; effervescent tabs for soln; unflavored, cherry vanilla, orange cream, lemon citrus, cherry berry flavors.
- Review of Factors Impacting Sport-Related Concussion Headaches
- Use of Disease Modifying Therapies for Multiple Sclerosis Has No Ill Effect on Pregnancy Outcomes
- Once-Daily Rivaroxaban 15 mg to 20 mg Increases Intracranial Hemorrhage Risk
Indications for EFFER-K:
Hypokalemia with or without metabolic alkalosis. Digitalis intoxication. Hypokalemic familial periodic paralysis. Prevention of potassium depletion when dietary intake is inadequate.
Take with food or immediately after a meal; sip slowly over 5–10 mins. 1 tab 1–4 times daily, based on patient requirement. Dissolve each 10mEq tab in 2–3oz of cold water or juice (if unflavored); dissolve each 20mEq tab in 3–4oz of cold water or juice (if unflavored); dissolve each 25mEq tab in 4oz of cold water or 12–16oz of cold juice (if unflavored).
Hyperkalemia. Chronic renal disease. Metabolic acidosis. Uncontrolled diabetes mellitus. Esophageal compression. Delayed gastric emptying. Intestinal obstruction/stricture. Peptic ulcer. Concomitant potassium-sparing diuretics (eg, spironolactone, triamterene).
Discontinue if GI bleed, ulceration, or other disturbances occur. Acidosis. Renal or cardiac disease. Monitor serum potassium and magnesium levels, renal function, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with potassium-sparing diuretics, ACE inhibitors, NSAIDs, beta-adrenergic blockers, heparin, low-salt foods, potassium-containing drugs, digitalis glycosides, others.
Hyperkalemia, nausea, vomiting, abdominal discomfort, diarrhea.
Tabs 10mEq, 20mEq—30; 25mEq—30, 100 (orange-flavored)
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a